**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 31597**

**Manuscript type: ORIGINAL ARTICLE**

***Basic Study***

**Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease**

Lin Z *et al*. IL-10 signaling interaction in pediatric IBD

Zhenwu Lin, Zhong Wang, John P Hegarty, Tony R Lin, Yunhua Wang, Sue Deiling, Rongling Wu, Neal J Thomas, Joanna Floros

**Zhenwu Lin, Yunhua Wang, Neal J Thomas, Joanna Floros,**CHILD Research, Department of Pediatrics,The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**Zhong Wang,Rongling Wu,** Division of Biostatistics, Department of Public Health Science, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**John P Hegarty, Tony R Lin, Sue Deiling,**Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**Joanna Floros,**Department of Obstetrics and Gynecology,The Pennsylvania State University, College of Medicine, Hershey, PA 17033, United States

**Zhenwu Lin,**Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 17033, United States

**Author contributions:** Lin Z and Wang Z contributed equally to this work; Lin Z designed the experimental approach and was responsible for troubleshooting, data collection and organization, and the overall supervision of the project; he worked with the statistician for data analysis, manuscript writing and submission, and the response to reviewers; Wang Z and Wu R contributed to the data analysis and presentation of the results, manuscript writing and revision; Hegarty PJ involved in grant writing, preliminary data preparation and genotype analysis; Lin RT contributed to IL10 genotype and genotyping data analysis (adult IBD and youth IBD), as well as IL10 gene expression in patients with different genotype; Wang Y Performed genotype analysis by PCR, gel electrophoresis, genotype scoring, and data sheet for analysis; Deiling S contributed to clinical sample collection and documentation; Thomas JN Involved study subject recruitment and clinical sample collection, and manuscript writing; Floros J Involved in experimental design, manage the research team, oversight of the project, data collection and presentation, manuscript writing, final critical reading before submission, response to reviewers and revise the manuscript for resubmission.

**supported by** a Children Miracle Network Research grant, No. 132698 to Lin Z (P.I.) and Thomas NJ (Co-P.I.) (2011-2013), and Floros J (P.I.) (2013-2014).

**Institutional review board statement:** All study protocols were approved by the Penn State University College of Medicine Institutional Review Board, study ID: PRAMS020105-A Jane 8, 2016. ATCC Material transfer agreement (MTA) Aug 28, 2012.

**Conflict-of-interest statement:** No conflict of interest exists for all authors.

**Data sharing statement:** Data will be shared freely to whoever requests them via contact of Zhenwu Lin (zxl13@psu.edu).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Zhenwu Lin, PhD, Senior Research Scientist,** Department of Pediatrics, College of Medicine Pennsylvania State University, 500 University Drive, Hershey, PA 17033, United States. [zxl13@psu.edu](mailto:zxl13@psu.edu)

**Telephone:** +1-717-2198591

**Fax**: +1-717-5310215

**Received:** November 27, 2016

**Peer-review started:** November 28, 2016

**First decision:** January 19, 2017

**Revised:** February 18, 2017

**Accepted:** June 1, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

to study the genetic association and epistatic interaction of the interleukin (IL)-10 and IL-10/STAT3 pathways in pediatric inflammatory bowel disease (IBD).

***Methods***

A total of 159 pediatric inflammatory IBD patients (Crohn’s disease, *n* = 136; ulcerative colitis, *n* = 23) and 129 matched controls were studied for genetic association of selected SNPs of the *IL-10* gene and the genes, *IL10RA*, *IL10RB*, *STAT3*, and *HO1*, from the IL10/STAT3 signaling pathway. As interactions between SNPs from different loci may significantly affect the associated risk for disease, additive (a) and dominant (d) modeling of SNP interactions was also performed to examine high-order epistasis between combinations of the individual SNPs.

***Results***

The results showed that IL-10 rs304496 was associated with pediatric IBD (*p* = 0.022), but no association was found for two other IL-10 SNPs, rs1800872 and rs2034498, or for SNPs in genes *IL10RA*, *IL10RB*, *STAT3*, and *HO-1*. However, analysis of epistatic interaction among these genes showed significant interactions, (1) between two IL-10 SNPs rs1800872 and rs3024496 (additive-additive *p* = 0.00015, Bonferroni p value (Bp) = 0.003); (2) between IL-10 RB rs2834167 and HO1 rs2071746 (dominant-additive, p = 0.0018, Bp = 0.039); and (3) among IL-10 rs1800872, IL10RB rs2834167, and HO1 rs2071746 (additive-dominant-additive, *p* = 0.00015, Bp = 0.005), as well as weak interactions among IL-10 rs1800872, IL-10 rs3024496, and IL-10 RA (additive-additive-additive, *p* = 0.003; Bp = 0.099), and among IL10RA, IL10RB, and HO1 genes (additive-dominant-additive, *p* = 0.008, Bp = 0.287).

***Conclusion***

These results indicate that both the *IL-10* gene itself, and through epistatic interaction with genes within the IL10/STAT3 signaling pathway, contribute to the risk of pediatric IBD.

**Key words:** Pediatric inflammatory bowel disease; interleukin-10, HO-1, Single nucleotide polymorphism; IL10-STAT3 pathway; epistatic interaction

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Inflammatory bowel disease (IBD) affects not only adults, but also children and newborn infants. Of the 163 genes currently associated with risk for development of IBD, only a few have been studied in pediatric patients. Here we found that one interleukin-10 genetic variation, rs304496, is associated with risk for pediatric IBD. Interleukin-10 (IL-10) restricts excessive immune responses during intestinal inflammation. We also demonstrate epistatic interactions between genetic variants within the IL10/STAT3 signaling pathway that contribute to a higher associated risk for pediatric IBD. These findings emphasize the importance of the IL10 pathway in a subgroup of IBD patients.

Lin Z, Wang Z, Hegarty JP, Lin TR, Wang Y, Deiling S, Wu R, Thomas NJ, Floros J. Genetic association and epistatic interaction of the interleukin-10 signaling pathway in pediatric inflammatory bowel disease. *World J Gastroenterol* 2017; In press

**Introduction**

Pediatric inflammatory bowel disease (IBD) has a distinct clinical phenotype from adult IBD[1]. Few of the 163 genes identified to be associated with adult IBD have been identified and functionally studied in pediatric IBD. A GWAS in the Polish population revealed that the genetic architecture is different between pediatric and adult-onset IBD[2]. Adult IBD associated genes NOD2 (Leu1007insC) and IRGM have been shown to be associated with increased risk of CD and ORMDL3 variant with susceptibility to UC in Lithuanian early-onset IBD patients[3]. The TRIM22-NOD2 network and signaling pathways and genetic factors are associated with very early-onset and adult IBD. Functional studies showed that variants of the tripartite motif containing 22 gene (*TRIM22*) disrupted its ability to regulate NOD2-dependent activity of interferon-β signaling and NFKB[4].

In addition, novel association of major histocompatibility complex haplotype with pediatric-onset IBD has been reported[5]. The multi-drug resistance gene *MDR1* SNPs C1236T and G2577A/T have also been shown to be associated with CD in an Algerian pediatric CD[6].

Mutations in IL-10 and IL-10 receptors IL10RA and IL10RB have been linked to VEO (very early onset) IBD[7-12]. Knockout mice lacking IL-10 develop IBD (inflammatory bowel disease)[13]. IL-10 and STAT3 have been identified as IBD-associated genes in children and adults[10,14-20]. The IL-10 gene is an anti-inflammatory cytokine and the IL10/STAT3 signaling pathway plays an important role in controlling inflammation and protecting the intestine tissue from damage[21,22]. During the IL-10 signaling transduction, IL-10 binds to receptors IL10RA and IL10RB, and activates Jak1 and Tyk2, leading to phosphorylation of STAT3. Then the activated STAT3 translocates into nucleus and regulates target gene transcription to promote an anti-inflammatory response[23,24].

Despite pronounced evidence of the role of the genes comprising IL10 and genes within the IL10/STAT3 signaling pathway, our knowledge about how they may interact with each other to determine IBD development is still very limited. Genetic interactions between different loci, i.e., epistasis, have been thought to be of paramount importance in complex diseases[25,26]. Given the underlying complex pathways, it is reasonable to hypothesize that the genes detected, affect IBD through a network of gene-gene interactions between genes, or SNP-SNP interactions within a gene. In this paper, we used a computational model[27] to analyze how epistatic interactions among polymorphic loci in the IL-10 gene and IL10/STAT3 pathways govern pediatric IBD in a case-control setting. The model can not only estimate low-order epistasis between a pair of loci, but also detect high-order epistasis among three loci, thereby it is equipped with a capacity to unravel etiological complexities of pediatric IBD. Furthermore, by integrating classic quantitative theory, this model dissects overall epistatic interaction into its underlying components. With this, one may be better understand the genetic machinery of this disease from a mechanistic aspect.

**Materials and Methods**

***Study samples***

Genomic DNA samples obtained from a total of 159 pediatric IBD patients [136 Crohn’s disease (CD); 23 ulcerative colitis (UC) were studied. The age of diagnosis for all patients was < 17 years old. The patients were Caucasian (*n* = 153) and African American (*n* = 6). Genomic DNA samples were obtained from the Crohn’s and Colitis Foundation of America (CCFA) DNA Databank (128 IBD (CD 118, UC 10) and the Pennsylvania State University IBD biobank (31 IBD; CD 18 and UC 13)[28]. Healthy genomic DNA control samples (*n* = 129) were obtained from CCFA (*n* = 70) and the Hershey Medical Center (*n* = 59). The race, age, and sex of the controls were matched to the study cases; none of the controls were identified with gastrointestinal related diseases (Table 1).

Informed consent was obtained for all patient samples retrieved from the Pennsylvania State University IBD Biobank and the Hershey Medical Center. All study protocols were approved by the Penn State University College of Medicine Institutional Review Board. CCFA genomic DNAs were collected from samples originating from the University of North Carolina at Chapel Hill, University of Chicago, Cedars-Sinai Hospital, Massachusetts General Hospital, University of Pittsburgh, and Mt. Sinai Hospital, with written informed parental or guardian consent.

***DNA isolation***

Genomic DNA (gDNA) samples were obtained from CCFA as noted above. The gDNA from Hershey Medical Center was isolated from blood samples or Epstein Bar virus (EBV) immortalized B cell lines using Qiagen DNA Mini Kits (Qiagen Inc. Valencia, CA, United States). After DNA concentration was measured with a Nanodrop ND-2000 spectrophotometer (Thermo Scientific, Wilmington, United States), the gDNA samples were stored at -80 oC until use.

***Selection criteria and study of SNPs from IL-10, IL10RA, IL10RB, STAT3, and HO-1***

Seven SNPs from these five genes were studied. These are rs1800872 (C-592>A), rs3024498 and rs3024496 from IL-10[23]; rs3135932 from IL10RA[7]; rs2834167 from IL10RB[7,29]; rs744166 from STAT3; and rs2071746 from HO-1[30,31]. The criteria for SNP selection were based a) on the potential relevance of these SNPs in the function and the regulation of genes, which have been associated with IBD and other diseases, and/or play a role in inflammatory processes; b) on the gene location, either within the coding region that changes the encoded amino acid, or at 5’ upstream or 3’UTR potentially affecting RNA transcription, RNA stability, or protein translation; and c) being polymorphic in the study samples as tested in our preliminary study and having MAF (minor allele frequency) information in existing databases. A summary of these SNPs is provided in Table 2, including genetic variation, chromosomal position, gene location, and disease implication.

***Genotype analysis***

The genotypeof all 7 SNPs were determined with PCR-based RFLP/cRFLP as described previously[32]. The PCR primers and related information are given in Table 3. Briefly, 100ng DNA were used for PCR in a 30 μl reaction volume. The PCR cycling profile was as follows: 95 oC for 2 min, 5 cycles at 95 oC for 30 s, 50 oC for 1 min, and 72 oC for 1 min, then 30 cycles at 95 oC for 30 s, 58 oC for 1 min, and 72 oC for 1 min, followed by a final extension step at 72 oC for 4 min. PCR products (5 μl) were digested with an appropriate restriction enzyme (Table 3) according to manufacturer’s instructions. The digested PCR products were separated by PAGE (8%), and the genotypes were scored according to the gel pattern of digested PCR products.

***Statistical analysis***

Single SNP analysis: By associating each single SNP with the disease, we calculated the genotype-based odds ratio (OR) and p-value based on Fisher’s exact test. We also calculated 95% confidence intervals for each odds ratio. The difference was considered as significant when *p* < 0. 05.

***Epistatic interaction analysis of IL-10 and IL-10 pathway genes***

Epistatic analysis: Epistasis, due to the interaction between two different loci, may play an important role in disease progression. By using two different SNPs simultaneously, epistasis may detect information that cannot be detected by single SNP analysis. We have developed a model of epistatic detection[27], which allows high-order epistasis due to the interaction among more than two loci to be characterized. This model was used to test high-order epistasis between, IL-10 and IL-10 receptors, IL-10 and STAT3, IL-10 and HO-1, and STAT3 and HO-1. This model not only allows the testing of additive (a) and dominant (d) effects at single SNPs, but is also able to detect the epistatic effects between 2 or 3 SNPs in a case–control study[27].

Four types of epistatic interactions for 2 SNPs, namely additive-additive (aa), additive-dominant (ad), dominant-additive (da), and dominant-dominant (dd) and 8 types of epistatic interactions for 3 SNPs, namely aaa, aad, ada, add, daa, dad, dda and ddd, were estimated and are discussed in this paper.

We estimated the pair-wise linkage disequilibria (LD) between these epistatic loci, which were detected to be non-significant, showing that these loci are segregating randomly in the population.

**Results**

***IL-10 rs304496 is associated with pediatric IBD***

There is limited information in terms of genetic association studies for pediatric IBD. The present study of pediatric IBD builds upon and extends findings from our previous genetic association study on adult IBD. We initially wished to confirm previous findings[20] as to whether IL10 was involved in pediatric IBD. Since published studies of IL-10 were done in adult IBD, we carried out a pilot study with adult IBD. We studied IL-10 association with 122 adult IBD (74 CD, 48 UC) cases (mean age 51 years) and 172 unrelated healthy controls from Hershey Medical Center using SNPlex Genotyping System[33,34]. The results indicated that 2 IL10 SNPs are significantly associated with IBD: rs1800872 *p* = 0.0056, OR = 1.753, and 95%CI: 1.190-2.643; and rs304498 *p* = 0.0008 OR = 0.43, and 95%CI: 0.26-0.7. This pilot genetic association study as well as other association studies of adult IBD, guided our selection of genes and SNPs for the present study.

In the present study, we wished to know whether IL10, shown previously to be associated with adult IBD is associated with pediatric IBD, and whether the IL10/STAT3 pathway plays a role in pediatric IBD. The study samples were 159 IBD (136 CD; 23 UC) and the 3 SNPs genotyped were rs1800872, rs3024496, and rs3024498. The results indicated (Table 4) that neither of the two SNPs, rs1800872 and rs3024498, that have been previously observed to be associated with adult IBD were associated with pediatric IBD (*p* = 0.71 and *p* = 0.616, respectively). The rs3024496 was the only SNP found to significantly associate with pediatric IBD (*p* = 0.022).

***No association with pediatric IBD was found for the IL-10 pathway genes, IL10RA, IL10RB, STAT3, and HO-1***

The IL10-STAT3 signaling pathway plays an important role in controlling inflammation in intestine. The IL10RA, IL10RB, and STAT3 are critical players in this pathway. IL10 and STAT3 have previously been identified to be associated with IBD in adult, while mutations in both IL-10 receptors A and B have been demonstrated to be associated with early onset IBD. The activated STAT3 pathway regulates expression of several critical anti-inflammatory genes, including HO-1, a potent anti-inflammation and anti-oxidant enzyme. Our genetic association study results indicate that none of these genes is significantly associated with pediatric IBD (Table 4).

***Epistatic interaction of SNP-SNP (rs3024496 and rs1800872) within the IL10 gene in pediatric IBD***

Based on previous genetic studies of the studied genes and their role in the IL-10 pathway[23,24], we speculated that some of the SNPs contribute to disease by interacting with other genes. To test this hypothesis we used our recently developed model[27] that has been proven to be genetically meaningful in our previous studies on IBD susceptibility genes[30,35,36].

First, we studied SNP-SNP interaction among 3 SNPs (rs1800872 and rs3024496, rs1800872 and rs3024498, and rs3024496 and rs3024498) within the IL10 gene of all possible combinations of additive and dominant models.

A significant epistatic interaction was only observed for rs1800872 and rs3024496 (*p* = 0.00015; Bp = 0. 003), see Table 5. A graphical depiction of this additive-additive (aa) model is shown in Figure 1. Although the IL-10 rs1800872 was shown by itself to associate with adult IBD but not associate with pediatric IBD (*p* = 0.71, Table 4), the present data indicate that it may still contribute to pediatric IBD via interaction with another IL-10 SNP, namely rs3024496.

***Epistatic interaction of the IL-10 gene with the IL-10 signaling pathway genes, IL-10 RB and HO1, in pediatric IBD***

We further analyzed gene-gene interactions between IL-10 and the other 4 genes, IL10RA, IL10RB, STAT3, and HO-1, involved in the IL10 signaling pathway. The results showed that none of the 3 IL-10 SNPs significantly interacted with the SNPs of the other 4 genes (Table 6). Although a low p value was observed for the IL-10 rs1800872 with either the IL10RA (aa, *p* = 0.046), IL10RB (aa, *p* = 0.029), or STAT3 (dd, *p* = 0.036), and for the IL-10 rs3024498 with the STAT3 (ad, *p* = 0.032; dd *p* = 0.029), none of these stands as significant after Bonferroni correction is applied. Only the interaction of the IL-10 rs3024496 with the IL10RA rs3135932 showed a low Bonferroni *p* value (aa *p* = 0.021, Bp = 0.433; ad *p* = 0.020, Bp = 0.426) (Table 6). A graphic depiction of the interaction model of IL-10 with IL10RA is shown in Figure 2A. From a single association study as described above, none of the SNPs of the 4 genes in the IL-10 signaling pathway was associated with pediatric IBD. However, we found that SNPs of the IL-10 RB and HO-1 genes contribute to pediatric IBD (da: *p* = 0.0018, Bp = 0.039) (Table 6) via gene-gene interaction. Graphic depictions for the model interactions between IL10RB and HO-1 are shown in Figure 2B.

***Epistatic interaction of the IL-10, rs3024496 and rs1800872, with the IL-10 RA, rs3135932, in pediatric IBD***

We next investigated whether the interaction of two IL-10 SNPs rs1800872 and rs3024496 affects further interaction of IL-10 with other genes. As shown in Table 7, in the presence of the two IL-10 SNPs, the association of IL10RA rs3135932 is increased remarkably from *p* = 0.16 (when analyzed by itself), to *p* = 0.046 (with rs1800872), *p* = 0.021 (with rs3024496) (Table 5) to *p* = 0.003 (with both rs1800872 and rs3024496) (Table 7). This epistatic interaction is an aaa model (Figure 3). However, the interaction of the two IL-10 SNPs did not exhibit any further observed effect on IL-10 interaction with the other genes, IL10RB, STAT3, and HO-1 (Table 7).

***Epistatic interaction of the IL-10 pathway genes IL10RA, IL10RB, STAT3, and HO1 in pediatric IBD***

Based on the epistatic interaction of IL10RB with HO1 (Table 6, Figure 2B), we further analyzed the effect of the IL10RB and HO1 interaction (in each of the 4 models aa, ad, da, and dd) on the contribution to IBD in conjunction with IL10, IL10RA, and STAT3. Eight types of epistatic interactions in each set of 3 SNPs were studied. As shown in Table 8, a significant effect was observed on the interaction of these two genes, IL10RB and HO-1, with the IL-10 gene rs1800872, *p* = 0.00015; Bp = 0.005. The model of the 3 gene interaction dIL10RBaHO1aIL10 is depicted in Figure 4. Moreover, weak interactions are also observed on the interaction of these two genes with IL10RA rs3135932 (aaa *p* = 0.023, Bp = 0.820; daa *p* = 0.008, Bp = 0.287) and with STAT3 rs744166 (daa *p* = 0.014, Bp = 0.491). As shown in Fig. 2B, the interaction model dIL10RBaHO1 for IL-10 and HO1 is significant (Bp = 0.039). The three SNPs interaction analysis indicates that this model is responsible for the interaction of the IL10RB and HO1 with the other genes, IL10, IL10RA, and STAT3, in the IL-10 pathway, as dIL10RBaHO1aIL10, dIL10RBaHO1aIL10RA, and dIL10RBaHO1aSTAT3, respectively.

The findings indicate that the interaction between IL10RB and HO1 may enhance their action with IL-10 and IL10RA and elevate the pathway activity in pediatric IBD. Considering that the HO1 is an important mediator of the anti-inflammatory effect of IL-10 and several mutations in IL10RB are associated with pediatric IBD, these gene-gene interactions may affect pathway function by regulating anti-inflammatory activity in pediatric IBD.

**DISCUSSION**

In the present study, we identified a genetic association of the IL-10 gene and the IL-10 signaling pathway with pediatric IBD and demonstrated that both SNP-SNP and gene-gene epistatic interactions contribute to pediatric IBD. The specific findings include the following: (1) IL-10 rs3024496 is identified to be associated with pediatric IBD; (2) an additive-additive interaction was found between IL-10 SNPs rs3024496 and rs1800872; (3) the SNP-SNP interaction in the IL-10 gene affects its action with IL-10 receptor IL10RA; (4) the IL-10 signaling pathway genes IL10RB and HO1 together are significantly associated with pediatric IBD via SNP-SNP interaction; and (5) a significant association of the 3 genes, IL10, IL10RB, and HO1, with pediatric IBD was identified from epistatic interaction analysis among 3 SNPs.

The IL-10 gene has been shown to be associated with adult IBD by GWASs. The most studied IL-10 SNP, -1082A>G (rs1800896), is thought as a potential for gene transcription regulation[7,14-16,37]. The IL-10 SNP rs3024496 is shown to be related to inflammatory response with increased levels of IgE to dust mite[38], or decrease production of IL-10 by peripheral blood leukocytes[39], and with prostate[40], and colorectal[41] cancer, but has not been shown to be associated with IBD. The IL-10 rs1800872 is associated with IBD[37] and also with increased serum IL-10 levels in CD[42,43], as well as with irritable bowel syndrome (IBS)[44], and cancer susceptibility[42,43,45,46]. In this study, we found that IL-10 rs3024496 is associated with pediatric IBD, and rs1800872, although by itself is not associated with pediatric IBD, appears to contribute to pediatric IBD via epistatic interaction with rs3024496.

Although currently more than 163 genes have been identified to be associated with IBD[47-50], only few of them have been studied in pediatric IBD. The estimate that a genetic contribution of the identified genes collectively represents only < 20% of the overall disease risk[47,51-55] indicates that other genetic/genomic and environmental factors may play a role in IBD pathogenesis. In the present study, we studied IL-10 gene contribution in pediatric IBD by analyzing its association with disease as well as its epistatic interaction with IL-10 pathway genes. Our results indicate, in addition to disease association of IL-10 itself, that SNP-SNP and gene-gene interactions contribute significantly to pediatric IBD.

Our results support that epistasis plays an important role in the formation and progression of human diseases[56,57]. Understanding gene-gene interaction is crucial to our understanding of the regulation of physiological function. When epistasis occurs, the presence of two or more particular loci may increase or reduce the risk of a disease more than would be expected from their independent effects[58]. A host of statistical models have been developed to analyze epistatic effects in different genetic designs[59,60].

Our recently developed model for multilocus epistatic interactions in case-control studies has proven to be genetically meaningful through the incorporation of traditional quantitative genetic principles into statistical models[27]. Using this model we have previously studied epistatic interaction between SNPs within the DLG5 gene and between IBD genes DLG5, OCTN1, IL23R, and NOD2[28,35,36], and found that epistatic interaction is an important component in IBD pathogenesis. In this study, we used the same method to study gene-gene interaction in IL-10 signaling transduction pathway. IL-10 signaling transduction occurs through binding of IL-10 to its receptors IL10RA and IL10RB to form a complex, with downstream molecules, Jak1 and Tyk2, activating STAT3[24,25]. IL10RA is specific to IL10, but IL10RB also interacts with several other cytokines. When either IL10RA or IL10RB is mutated, the signals from IL-10 cannot be received and the resulting inflammation causes tissue damage in the gastrointestinal system[23,24]. A significant epistatic interaction was observed between two IL-10 SNPs, resulting in a significant effect of IL-10 interaction with ILRA, but not with IL10RB (Table 7). This indicates that IL-10 may interact with receptor IL10RA, which plays a role in the initiation of the signaling pathway.

We also observed a significant epistatic interaction between IL10, IL10RB, and the downstream pathway target HO1 gene (Table 8). The key factor for interaction of these 3 genes is IL10RB that interacts strongly with HO1. This finding indicates that the IL-10 receptors IL10RA and IL10RB are likely to function differently in the IL-10 pathway in pediatric IBD. Although HO1 was not found to be associated with IBD[61], it has been shown to be associated with other diseases such as asthma and allergy[44,61]. HO1 is a potent enzyme of anti-inflammation, and has a very important function of the IL-10 pathway in controlling inflammation[14].

Although STAT3 is a critical component of the IL10-STAT3 pathway[23,24], no significant interaction was observed between IL-10 and/or IL-10 receptors with STAT3, indicating that other factor(s) may play a role between these 2 genes in the pathway. We know that in the IL-10 pathway, upon binding of IL-10 to cell receptors IL10RA and IL10RB, the IL-10 receptor complex members JAK1 and Tyk2 are activated and catalyze phosphorylation of themselves and then of IL10RA[3,4], thereby forming docking site for STAT3. STAT3 is phosphorylated by JAK1 and Tyk2, and this phosphorylation causes STAT3 dimerization and translocation to the nucleus where it can induce expression of its target genes including HO-1. Therefore, we speculate that JAK1 and Tyk2 play a role in pediatric IBD by their activity in the phosphorylation and activation of STAT3 in IL-10 signaling pathway.

Recently, pediatric/VEO (very early onset) IBD has been suggested to be a distinct form of IBD[11,62], and SNPs in IL10 and IL10 receptors have been associated with VEO-IBD[7-12]. In the present study, we identified IL10 SNP of IL-10 rs3024496 to be associated with pediatric IBD; this has not been shown to be associated with adult IBD. However, our results did not show a genetic association of the IL10 rs1800872 and STAT3 rs744166 with pediatric IBD which have been shown to be associated with adult IBD. Our present study, also showed that epistatic interactions of IL-10 with genes IL10RA, IL10RB, STAT3, and HO-1 contribute to pediatric IBD. Their physiological function in the regulation of the anti-inflammatory pathway in response to pro-inflammatory stimulation, and protection of diseased tissues from damage is currently not well studied. IBD is a major gastrointestinal disease affecting 1.4 million people in the United States. About 15%-25% of IBD patients are diagnosed in childhood[16,23]. Specific investigation targeting the IL-10 signaling pathway in pediatric IBD pathogenesis will help to understand the pathogenesis of pediatric IBD, and may provide target molecules and pathways to potentially develop anti-inflammatory agents for clinical treatment of pediatric IBD.

Other cytokines have also shown to be in the inflammatory process in IBD. Studies on correlation between NO and IL17A, IL-23, and IL-6 levels in plasma of IBD patients indicated that the IL23/IL17A axis and NO synthase pathway are involved in inflammation regulation in IBD[63].

In summary, IL-10 is associated with pediatric IBD, and the IL-10 signaling pathway that plays an important role in anti-inflammation. We propose, as depicted in Figure 5, that in pediatric IBD pathogenesis, (1) IL-10 via its interaction with receptor IL-10 RA, and then together with receptor IL-10 RB are critical for the initial step of the signaling transduction; (2) IL-10 via its interaction with receptor IL-10 RB plays a key role in regulating gene transcription in anti-inflammation enzymes, such as the HO1, that may lead to an anti-inflammatory response; and (3) no significant interaction was found between IL-10 and IL-10 receptors with STAT3, a key molecule in the IL-10 pathway. However, further investigation may provide insight as to whether JAK1 and Tyk2 are involved in pediatric IBD, via potential interactions with IL10RA and IL10RB where together could phosphorylate and activate STAT3.

**Acknowledgements**  
Study samples were provided by Crohn’s and Colitis Foundation of American and the Pennsylvania State University Hershey Medical Center and Hershey Biobank.

**COMMENTS**

***Background***

Knockout mice lacking IL-10 develop inflammatory bowel disease (IBD), and mutations in IL-10 and IL-10 receptors IL10RA and IL10RB have been linked to VEO (very early onset) IBD. Both IL-10 and STAT3 have been identified as IBD-associated genes in adults, but these are not well studied in pediatric IBD.

***Research frontiers***

Mutations of IL10 and its receptors have been identified recently in VEO IBD. We studied genetic association of IL10 and genes in IL10/STAT3 pathway with pediatric IBD.

Genetic interactions between different loci, i.e., epistasis, have been thought to be of paramount importance in complex diseases. In this paper, we used a computational model to analyze how epistatic interactions among polymorphic loci in the IL-10 gene and IL10/STAT3 pathway govern pediatric IBD in a case-control setting.

***Innovations and breakthrough***

Despite pronounced evidence of the role of the genes comprising IL10 and genes within the IL10/STAT3 signaling pathway, our knowledge about how they interact with each other to determine IBD development is still very limited. In this paper, we have identified IL10 variation associated with pediatric IBD, and found a number of epistatic interactions of IL10 with genes in IL10/STAT3 pathway contributing to pediatric IBD. The contribution of interactions of IL10/STAT3 pathway and anti-inflammatory HO-1 gene to IBD indicated that IL10 plays a role in the control of inflammation in IBD.

***Applications***

The findings may help to understand the function of IL10 and IL10 pathway in the control of inflammation in IBD, and identify target molecules for clinical investigation and drug discovery for controlling inflammation in IBD.

***Peer-review***

The authors report novel data. The obtained results indicate that both the IL-10 gene, and its epistatic interaction with genes within its signaling pathway, are related to the pediatric IBD.

**References**

1 **Van Limbergen J**, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. *Gastroenterology* 2008; **135**: 1114-1122 [PMID: 18725221 DOI: 10.1053/j.gastro.2008.06.081]

2 **Ostrowski J**, Paziewska A, Lazowska I, Ambrozkiewicz F, Goryca K, Kulecka M, Rawa T, Karczmarski J, Dabrowska M, Zeber-Lubecka N, Tomecki R, Kluska A, Balabas A, Piatkowska M, Paczkowska K, Kierkus J, Socha P, Lodyga M, Rydzewska G, Klopocka M, Mierzwa G, Iwanczak B, Krzesiek E, Bak-Drabik K, Walkowiak J, Klincewicz B, Radwan P, Grzybowska-Chlebowczyk U, Landowski P, Jankowska A, Korczowski B, Starzynska T, Albrecht P, Mikula M. Genetic architecture differences between pediatric and adult-onset inflammatory bowel diseases in the Polish population. *Sci Rep* 2016; **6**: 39831 [PMID: 28008999 DOI: 10.1038/srep39831]

3 **Pranculienė G**, Steponaitienė R, Skiecevičienė J, Kučinskienė R, Kiudelis G, Adamonis K, Labanauskas L, Kupčinskas L. Associations between NOD2, IRGM and ORMDL3 polymorphisms and pediatric-onset inflammatory bowel disease in the Lithuanian population. *Medicina (Kaunas)* 2016; **52**: 325-330 [PMID: 27932194 DOI: 10.1016/j.medici.2016.11.006]

4 **Li Q**, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, Hao K, Dinarzo A, Hoffman G, Kidd BA, Murchie R, Al Adham Z, Guo C, Kotlarz D, Cutz E, Walters TD, Shouval DS, Curran M, Dobrin R, Brodmerkel C, Snapper SB, Klein C, Brumell JH, Hu M, Nanan R, Snanter-Nanan B, Wong M, Le Deist F, Haddad E, Roifman CM, Deslandres C, Griffiths AM, Gaskin KJ, Uhlig HH, Schadt EE, Muise AM. Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. *Gastroenterology* 2016; **150**: 1196-1207 [PMID: 26836588 DOI: 10.1053/j.gastro.2016.01.031]

5 **Kolho KL**, Paakkanen R, Lepistö A, Wennerstöm A, Meri S, Lokki ML. Novel Associations Between Major Histocompatibility Complex and Pediatric-onset Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr* 2016; **62**: 567-572 [PMID: 26398154 DOI: 10.1097/MPG.0000000000000984]

6 **Bouzidi A**, Mesbah-Amroun H, Boukercha A, Benhassine F, Belboueb R, Berkouk K, Messadi W, Touil-Boukoffa C. Association between MDR1 gene polymorphisms and the risk of Crohn's disease in a cohort of Algerian pediatric patients. *Pediatr Res* 2016; **80**: 837-843 [PMID: 27603561 DOI: 10.1038/pr.2016.163]

7 **Glocker EO**, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med* 2009; **361**: 2033-2045 [PMID: 19890111 DOI: 10.1056/NEJMoa0907206]

8 **Christodoulou K**, Wiskin AE, Gibson J, Tapper W, Willis C, Afzal NA, Upstill-Goddard R, Holloway JW, Simpson MA, Beattie RM, Collins A, Ennis S. Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. *Gut* 2013; **62**: 977-984 [PMID: 22543157 DOI: 10.1136/gutjnl-2011-301833]

9 **Glocker EO**, Frede N, Perro M, Sebire N, Elawad M, Shah N, Grimbacher B. Infant colitis--it's in the genes. *Lancet* 2010; **376**: 1272 [PMID: 20934598 DOI: 10.1016/S0140-6736(10)61008-2]

10 **Shim JO**, Hwang S, Yang HR, Moon JS, Chang JY, Ko JS, Park SS, Kang GH, Kim WS, Seo JK. Interleukin-10 receptor mutations in children with neonatal-onset Crohn's disease and intractable ulcerating enterocolitis. *Eur J Gastroenterol Hepatol* 2013; **25**: 1235-1240 [PMID: 23839161 DOI: 10.1097/MEG.0b013e328361a4f9]

11 **Shim JO**, Seo JK. Very early-onset inflammatory bowel disease (IBD) in infancy is a different disease entity from adult-onset IBD; one form of interleukin-10 receptor mutations. *J Hum Genet* 2014; **59**: 337-341 [PMID: 24785691 DOI: 10.1038/jhg.2014.32]

12 **Moran CJ**, Walters TD, Guo CH, Kugathasan S, Klein C, Turner D, Wolters VM, Bandsma RH, Mouzaki M, Zachos M, Langer JC, Cutz E, Benseler SM, Roifman CM, Silverberg MS, Griffiths AM, Snapper SB, Muise AM. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. *Inflamm Bowel Dis* 2013; **19**: 115-123 [PMID: 22550014 DOI: 10.1002/ibd.22974]

13 **Kühn R**, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 1993; **75**: 263-274 [PMID: 8402911 DOI: 10.1016/0092-8674(93)80068-P]

14 **Seo JK**. Pediatric inflammatory bowel disease (IBD): phenotypic, genetic and therapeutic differences between early-onset and adult-onset IBD. *Korean J Ped Gastroenterol Nutr* 2011; **14**: 1-25 [DOI: 10.5223/kjpgn.2011.14.1.1]

15 **Doecke JD**, Simms LA, Zhao ZZ, Huang N, Hanigan K, Krishnaprasad K, Roberts RL, Andrews JM, Mahy G, Bampton P, Lewindon P, Florin T, Lawrance IC, Gearry RB, Montgomery GW, Radford-Smith GL. Genetic susceptibility in IBD: overlap between ulcerative colitis and Crohn's disease. *Inflamm Bowel Dis* 2013; **19**: 240-245 [PMID: 23348120 DOI: 10.1097/MIB.0b013e3182810041]

16 **Ruemmele FM**, El Khoury MG, Talbotec C, Maurage C, Mougenot JF, Schmitz J, Goulet O. Characteristics of inflammatory bowel disease with onset during the first year of life. *J Pediatr Gastroenterol Nutr* 2006; **43**: 603-609 [PMID: 17130735 DOI: 10.1097/01.mpg.0000237938.12674.e3]

17 **Benchimol EI**, Guttmann A, Griffiths AM, Rabeneck L, Mack DR, Brill H, Howard J, Guan J, To T. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. *Gut* 2009; **58**: 1490-1497 [PMID: 19651626 DOI: 10.1136/gut.2009.188383]

18 **Benchimol EI**, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. *Inflamm Bowel Dis* 2011; **17**: 423-439 [PMID: 20564651 DOI: 10.1002/ibd.21349]

19 **Baldassano RN**, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. *Gastroenterol Clin North Am* 1999; **28**: 445-458 [PMID: 10372276 DOI: 10.1016/S0889-8553(05)70064-9]

20 **Franke A**, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. *Nat Genet* 2008; **40**: 713-715 [PMID: 18438405 DOI: 10.1038/ng.148]

21 **Murray PJ**. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. *Curr Opin Pharmacol* 2006; **6**: 379-386 [PMID: 16713356 DOI: 10.1016/j.coph.2006.01.010]

22 **Brand S**. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. *Gut* 2009; **58**: 1152-1167 [PMID: 19592695 DOI: 10.1136/gut.2008.163667]

23 **Bernstein CN**, Blanchard JF. The epidemiology of Crohn's disease. *Gastroenterology* 1999; **116**: 1503-1504 [PMID: 10391739 DOI: 10.1016/S0016-5085(99)70522-6]

24 **Shouval DS**, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, Mascanfroni ID, Al Adham Z, Lavoie S, Ibourk M, Nguyen DD, Samsom JN, Escher JC, Somech R, Weiss B, Beier R, Conklin LS, Ebens CL, Santos FG, Ferreira AR, Sherlock M, Bhan AK, Müller W, Mora JR, Quintana FJ, Klein C, Muise AM, Horwitz BH, Snapper SB. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. *Immunity* 2014; **40**: 706-719 [PMID: 24792912 DOI: 10.1016/j.immuni.2014.03.011]

25 **Carlborg O**, Haley CS. Epistasis: too often neglected in complex trait studies? *Nat Rev Genet* 2004; **5**: 618-625 [PMID: 15266344 DOI: 10.1038/nrg1407]

26 **Mackay TF**, Moore JH. Why epistasis is important for tackling complex human disease genetics. *Genome Med* 2014; **6**: 124 [PMID: 25031624 DOI: 10.1186/gm561]

27 **Wang Z**, Liu T, Lin Z, Hegarty J, Koltun WA, Wu R. A general model for multilocus epistatic interactions in case-control studies. *PLoS One* 2010; **5**: e11384 [PMID: 20814428 DOI: 10.1371/journal.pone.0011384]

28 **Lin Z**, Hegarty JP, John G, Berg A, Wang Z, Sehgal R, Pastor DM, Wang Y, Harris LR, Poritz LS, Schreiber S, Koltun WA. NOD2 mutations affect muramyl dipeptide stimulation of human B lymphocytes and interact with other IBD-associated genes. *Dig Dis Sci* 2013; **58**: 2599-2607 [PMID: 23709157 DOI: 10.1007/s10620-013-2696-8]

29 **Tseng LH**, Storer B, Petersdorf E, Lin MT, Chien JW, Grogan BM, Malkki M, Chen PJ, Zhao LP, Martin PJ, Hansen JA. IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. *Transplantation* 2009; **87**: 704-710 [PMID: 19295315 DOI: 10.1097/TP.0b013e318195c474]

30 **Andersen V**, Ernst A, Christensen J, Østergaard M, Jacobsen BA, Tjønneland A, Krarup HB, Vogel U. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. *BMC Med Genet* 2010; **11**: 82 [PMID: 20509889 DOI: 10.1186/1471-2350-11-82]

31 **Ono K**, Goto Y, Takagi S, Baba S, Tago N, Nonogi H, Iwai N. A promoter variant of the heme oxygenase-1 gene may reduce the incidence of ischemic heart disease in Japanese. *Atherosclerosis* 2004; **173**: 315-319 [PMID: 15064108 DOI: 10.1016/j.atherosclerosis.2003.11.021]

32 **Lin Z**, Cui X, Li H. Multiplex genotype determination at a large number of gene loci. *Proc Natl Acad Sci USA* 1996; **93**: 2582-2587 [PMID: 8637917 DOI: 10.1073/pnas.93.6.2582]

33 **De la Vega FM**, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. *Mutat Res* 2005; **573**: 111-135 [PMID: 15829242 DOI: 10.1016/j.mrfmmm.2005.01.008]

34 **Tobler AR**, Short S, Andersen MR, Paner TM, Briggs JC, Lambert SM, Wu PP, Wang Y, Spoonde AY, Koehler RT, Peyret N, Chen C, Broomer AJ, Ridzon DA, Zhou H, Hoo BS, Hayashibara KC, Leong LN, Ma CN, Rosenblum BB, Day JP, Ziegle JS, De La Vega FM, Rhodes MD, Hennessy KM, Wenz HM. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. *J Biomol Tech* 2005; **16**: 398-406 [PMID: 16522862]

35 **Li X**, Sui Y, Liu T, Wang J, Li Y, Lin Z, Hegarty J, Koltun WA, Wang Z, Wu R. A model for family-based case-control studies of genetic imprinting and epistasis. *Brief Bioinform* 2014; **15**: 1069-1079 [PMID: 23887693 DOI: 10.1093/bib/bbt050]

36 **Lin Z**, Hegarty JP, Berb A, Wang Z, Kelly AA, Wang Y, Poritz LS, Wu R, Koltun WA. DLG5 P1371Q is associated with inflammatory bowel disease and complementary to R30Q in disease susceptibility. *Swiss Med Wkly* 2011; **141**: w13290 [PMID: 22065243 DOI: 10.4414/smw.2011.13290]

37 **Zhu H**, Lei X, Liu Q, Wang Y. Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: a meta-analysis based on 17,585 subjects. *Cytokine* 2013; **61**: 146-153 [PMID: 23046617 DOI: 10.1016/j.cyto.2012.09.009]

38 **Hunninghake GM**, Soto-Quirós ME, Lasky-Su J, Avila L, Ly NP, Liang C, Klanderman BJ, Raby BA, Gold DR, Weiss ST, Celedón JC. Dust mite exposure modifies the effect of functional IL10 polymorphisms on allergy and asthma exacerbations. *J Allergy Clin Immunol* 2008; **122**: 93-8, 98.e1-5 [PMID: 18440625 DOI: 10.1016/j.jaci.2008.03.015]

39 **Figueiredo CA**, Barreto ML, Alcantara-Neves NM, Rodrigues LC, Cooper PJ, Cruz AA, Pontes-de-Carvalho LC, Lemaire DC, dos Santos Costa R, Amorim LD, Vergara C, Rafaels N, Gao L, Foster C, Campbell M, Mathias RA, Barnes KC. Coassociations between IL10 polymorphisms, IL-10 production, helminth infection, and asthma/wheeze in an urban tropical population in Brazil. *J Allergy Clin Immunol* 2013; **131**: 1683-1690 [PMID: 23273955 DOI: 10.1016/j.jaci.2012.10.043]

40 **Wang MH**, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. *Prostate* 2009; **69**: 874-885 [PMID: 19267370 DOI: 10.1002/pros.20933]

41 **Tsilidis KK**, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, Visvanathan K, Platz EA. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. *Cancer Causes Control* 2009; **20**: 1739-1751 [PMID: 19760027 DOI: 10.1007/s10552-009-9427-7]

42 **Chen TK**, Lee JH, Yu HH, Yang YH, Wang LC, Lin YT, Chiang BL. Association between human IL-10 gene polymorphisms and serum IL-10 level in patients with food allergy. *J Formos Med Assoc* 2012; **111**: 686-692 [PMID: 23265747 DOI: 10.1016/j.jfma.2011.11.027]

43 **Xie G**, Myint PK, Zaman MJ, Li Y, Zhao L, Shi P, Ren F, Wu Y. Relationship of serum interleukin-10 and its genetic variations with ischemic stroke in a Chinese general population. *PLoS One* 2013; **8**: e74126 [PMID: 24040186 DOI: 10.1371/journal.pone.0074126]

44 **Qin SY**, Jiang HX, Lu DH, Zhou Y. Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis. *World J Gastroenterol* 2013; **19**: 9472-9480 [PMID: 24409078 DOI: 10.3748/wjg.v19.i48.9472]

45 **Sun JM**, Li Q, Gu HY, Chen YJ, Wei JS, Zhu Q, Chen L. Interleukin 10 rs1800872 T& gt; G polymorphism was associated with an increased risk of esophageal cancer in a Chinese population. *Asian Pac J Cancer Prev* 2013; **14**: 3443-3447 [PMID: 23886125 DOI: doi.org/10.7314/apjcp.2013.14.6.3443]

46 **Zhang YM**, Zhou XC, Xu Z, Tang CJ. Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. *Genet Mol Res* 2012; **11**: 3389-3397 [PMID: 23079832 DOI: 10.4238/2012].September.25.7]

47 **Xavier RJ**, Rioux JD. Genome-wide association studies: a new window into immune-mediated diseases. *Nat Rev Immunol* 2008; **8**: 631-643 [PMID: 18654571 DOI: 10.1038/nri2361]

48 **Imielinski M**, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D; Western Regional Alliance for Pediatric IBD, Silber G, Wrobel I, Quiros A; International IBD Genetics Consortium, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E; Belgian-French IBD Consortium; Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Silverberg MS, Satsangi J, Hakonarson H.. Common variants at five new loci associated with early-onset inflammatory bowel disease. *Nat Genet* 2009; **41**: 1335-1340 [PMID: 19915574 DOI: 10.1038/ng.489]

49 **Parkes M**, McGovern DP, Franke A, Taylor K. 33 New Crohn's disease susceptibility genes and loci identified by the international IBD Genetics Consortium. *Gastroenterology* 2010; **138**: S115 Available from: URL: <https://www.ibdgenetics.org/assets/ddw-cd-parkes.pdf>

50 **Rioux J**. International IBD Genetic consortium identifies >50 genetic risk factors for ulcerative colitis. *Gastroenterology* 2010; **139**: e19 [DOI: 10.1053/j.gastro.2010.05.071]

51 **Cho JH**. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 2008; **8**: 458-466 [PMID: 18500230 DOI: 10.1038/nri2340]

52 **Rioux JD**, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet* 2007; **39**: 596-604 [PMID: 17435756 DOI: 10.1038/ng203]

53 **Wellcome Trust Case Control Consortium**. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007; **447**: 661-678 [PMID: 17554300 DOI: 10.1038/nature05911]

54 **Duerr RH**, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 2006; **314**: 1461-1463 [PMID: 17068223 DOI: 10.1126/science.1135245]

55 **Yamazaki K**, McGovern D, Ragoussis J, Paolucci M, Butler H, Jewell D, Cardon L, Takazoe M, Tanaka T, Ichimori T, Saito S, Sekine A, Iida A, Takahashi A, Tsunoda T, Lathrop M, Nakamura Y. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. *Hum Mol Genet* 2005; **14**: 3499-3506 [PMID: 16221758 DOI: 10.1093/hmg/ddi379]

56 **Martin MP**, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J, Wilson M, O'Brien SJ, Carrington M. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. *Nat Genet* 2002; **31**: 429-434 [PMID: 12134147 DOI: 10.1038/ng934]

57 **Gabutero E**, Moore C, Mallal S, Stewart G, Williamson P. Interaction between allelic variation in IL12B and CCR5 affects the development of AIDS: IL12B/CCR5 interaction and HIV/AIDS. *AIDS* 2007; **21**: 65-69 [PMID: 17148969 DOI: 10.1097/QAD.0b013e3280117f49]

58 **Moore JH**, Williams SM. Epistasis and its implications for personal genetics. *Am J Hum Genet* 2009; **85**: 309-320 [PMID: 19733727 DOI: 10.1016/j.ajhg.2009.08.006]

59 **Zhang Y**, Liu JS. Bayesian inference of epistatic interactions in case-control studies. *Nat Genet* 2007; **39**: 1167-1173 [PMID: 17721534 DOI: 10.1038/ng2110]

60 **Gayán J**, González-Pérez A, Bermudo F, Sáez ME, Royo JL, Quintas A, Galan JJ, Morón FJ, Ramirez-Lorca R, Real LM, Ruiz A. A method for detecting epistasis in genome-wide studies using case-control multi-locus association analysis. *BMC Genomics* 2008; **9**: 360 [PMID: 18667089 DOI: 10.1186/1471-2164-9-360]

61 **Shah N**, Kammermeier J, Elawad M, Glocker EO. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. *Curr Allergy Asthma Rep* 2012; **12**: 373-379 [PMID: 22890722 DOI: 10.1007/s11882-012-0286-z]

62 **Ruemmele FM**. Pediatric inflammatory bowel diseases: coming of age. *Curr Opin Gastroenterol* 2010; **26**: 332-336 [PMID: 20571385 DOI: 10.1097/MOG.0b013e328339ec2d]

63 **Rafa H**, Saoula H, Belkhelfa M, Medjeber O, Soufli I, Toumi R, de Launoit Y, Moralès O, Nakmouche M, Delhem N, Touil-Boukoffa C. IL-23/IL-17A axis correlates with the nitric oxide pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid. *J Interferon Cytokine Res* 2013; **33**: 355-368 [PMID: 23472658 DOI: 10.1089/jir.2012.0063]

**P-Reviewer:** Annese V, Touil-Boukoffa C **S-Editor:** Gong ZM

**L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**


Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Epistatic interaction between *IL-10* SNPs rs3024496 and rs1800872**. Graphic depiction of epistatic interaction between the IL-10 SNPs, rs3024496 and rs1800872. Four interaction models for rs3024496 and rs1800872 are shown. The additive-additive model is significant (Bp = 0.003), the additive-dominant model is weak (Bp = 0. 216), and the other 2 models are not observed (Bp = 1, no color).



**Figure 2 Gene-gene interaction between *IL-10 and IL10RA, IL10RB,* and *HO-1* in pediatric inflammatory bowel disease.** A: Graphic depiction of epistatic interaction between the IL-10 SNP rs3024496 and the IL10RA rs3135932. Four interaction models for rs3024496 and rs3135932 are shown. The additive-additive and additive-dominant models are both weak (Bp = 0.433 and 0.426 respectively), and the other 2 models are not observed (Bp = 1, no color). B: Graphical depiction of epistatic interaction between the HO1 rs2071746 and the IL10RB rs2834167. Four interaction models for rs3024496 and rs3135932 are shown. Only the additive-dominant model is significant (Bp = 0.039), and the other 3 models are not observed (Bp = 1, no color). Bp: Bonferroni correction p value. The levels of Bp values are shown in the bar as shades of blue color from none (Bp = 1) to high (Bp = 0.001).



**Figure 3 Epistatic interaction of two *IL-10* SNPs, rs1800872 and rs3024496, with *IL10RA, IL10RB, STAT3*, and *HO-1* in pediatric inflammatory bowel disease.** Graphic depiction of epistatic interaction of the IL-10 SNPs, rs3024496 and rs1800872, with the IL10RA rs3135932. All the interaction models analyzed for the IL-10 SNPs, rs3024496 and rs1800872, with the IL10RA rs3135932 are shown. However, only one significant interaction model additive-additive-additive (a1a2a3) was observed (p = 0.003, Bp = 0.099). Levels of Bp values are shown in the bar as shades of blue color from none (Bp = 1) to high (Bp = 0.001). a1, d1, a2, d2, a3, d3: Letters, a and d, are for interaction model additive and dominant respectively; Numbers 1, 2, and 3 depict the IL-10 rs3024496, IL-10 rs1800872, and ILRA rs3135932, respectively. The contribution of a single SNP in an interaction model could be either a or d (a1 and d1 for SNP #1, a2 and d2 for SNP #2, and a3 and d3 for SNP #3). The interaction models for 2 and 3 SNPs are the combination of the 2 and 3 SNPs; such as, a1a2 for SNPs 1 and 2, and a1a2a3 for SNPs 1, 2, and 3.



**Figure 4 Epistatic interaction of *IL10RB* and *HO-1* with IL10 (3 SNPs), *IL10RA*, and *STAT3* in pediatric inflammatory bowel disease.** Graphic depiction of epistatic interaction of the IL-10 rs1800872, IL10RB rs2834167, and HO-1 rs2071746. Of all the interaction models analyzed, a 3-SNP interaction (a1d2a3) for IL-10 rs1800872, IL10RB rs2834167, and HO-1 rs2071746 is significant (Bp = 0.005). The levels of Bp values are shown in the bar as shades of blue color from none (Bp = 1) to high (Bp = 0.001). a1, d1, a2, d2, a3, d3: Letters, a and d, denote interaction models, additive and dominant respectively. Numbers 1, 2, and 3 are for IL-10 rs1800872, ILRB rs2834167, and HO1 rs2071746, respectively. The contribution of a single SNP in an interaction model could be either a or d: a1 and d1 for SNP #1, a2 and d2 for SNP #2, and a3 and d3 for SNP #3. The interaction models for 2 and 3 SNPs are the combination of 2 and 3 SNPs (e.g. a1a2 for SNPs 1 and 2, and a1a2a3 for SNPs 1, 2, and 3).



**Figure 5 Summary of gene function and epistatic interaction of the IL10/STAT3 signaling pathway in pediatric inflammatory bowel disease.** In the IL-10 pathway genes, genetic variations in IL-10 and STAT3 are associated with adult IBD, and genetic mutations identified from *IL10RA* and *IL-10RB* are associated with pediatric/very early onset IBD (published data). In this study, we found SNP-SNP epistatic interaction within IL10 gene, between *IL10* and *IL10RA* genes, and between IL10RB and HO1 genes. We also found epistatic interaction among 3 SNPs between two genes IL10 (2 SNPs) and IL10RA, and among three genes IL10, IL10RB and HO1. IBD: inflammatory bowel disease.

**Table 1 Study samples**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Samples** | **Number** | **Sex** | **Race** | **Age at diagnosis** |
| IBD | 159 | Male 85, Female 74 | white 153, black 6 | 13.1 |
| CD | 136 | Male 77, Female 59 | white 130, black 6 | 13.1 |
| CCFA | 118 | Male 65, Female 53 | white 112, black 6 | 13 |
| Hershey | 18 | Male 12, Female 6 | white 18 | 13.4 |
| UC | 23 | Male 9, Female 14 | white 23 | 13.3 |
| CCFA | 10 | Male 5, Female 5 | white 10 | 12.9 |
| Hershey | 13 | Male 4, Female 9 | white 13 | 13.6 |
| Control | 129 | Male 65, Female 64 | white 121, black 7, unknown 1 | 17.5 |

**Table 2 Study SNPs for *IL-10*, *IL10RA*, *IL10RB, STAT3*, and *HO-1* genes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP ID** | **Chromsomal position** | **Variation** | **GeneLocation** | **Disease implication** | **Ref.** |
| *IL10* | rs1800872 | 206946407 | C-592>A | 5'-upstream | Associated with IBD | [37] |
| rs3024498 | 206941529 | c.T>C | 3'-untralated region | Associated with colorectal cancer | [41] |
| rs3024496 | 206941864 | A>G | 3'-untralated region | Associated with IBD and colorectal cancer, with decreased IL10, with increased IgE levels | [37-39,41] |
| *IL10-RA* | rs3135932 | 117864063 | c.A247>G, p.Ser159Gly | coding region | Mutations (other than the studied SNP) associated with pediatric IBD | [7,10,12] |
| *IL10-RB* | rs2834167 | 34640788 | c.A>G, p.Lys(A)47Glu(G) | coding region | Mutations (other than the studied SNP) associated with pediatric IBD | [7-11] |
| *STAT3* | rs744166 | 404514201 | A>G | Intron 1 (closer to Exon2) | Associated with IBD | [20] |
| *HO-1* | rs2071746 | 3577672 | A413>T | 5'-upstream | No association with IBD, Associated with asthma and allergy, anti-inflammation, anti-oxidant | [30,31] |

**Table 3 PCR-RFLP method for genotyping *IL10, IL10RA, IL10RB, STAT3* and *HO-1* genes**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP ID** | **Variant** | **PCR amplication** | | **RFLP** | |
| **Primers1** | **Product (bp)** | **Restriction enzyme** | **Recognition site** |
| *IL10* | rs1800872 | G>T | IL2f: 5'-AACTTAGGCAGTCACCTTAGG-3'  IL2r: 5'-CATCCTGTGACCCCTCCAGT-3' | 149 | *Sca* I | T yes; G No |
| rs3024498 | T>C | IL5f: 5'-GCTCCtTGGTTTCTCTTCCTA AG-3'  IL5r: 5'-AGAAGCTTCCATTCCAAGCC TGA-3' | 137 | HpyCH4V | C yes; T No |
| rs3024496 | A>G | IL4f: 5'-GTATCAGAGGTAATAAATATTC cAT-3'  IL4r: 5'-TAGAAGCATACATGACAATGAAG-3' | 178 | *Nla* III | G yes; A No |
| *IL10-RA* | rs3135932 | A>G | RA3f: 5'-CCCGCAAATGACACATATGgA-3'  RA3r: 5'-AGT TCCCAATGGCACACAAGG-3' | 172 | *Mn* I | G yes; A No |
| *IL10-RB* | rs2834167 | A>G | RB3f: 5'-GCCATAGAGGAGAACCAAGTG-3'  RB3r: 5'-GCTGTGAAAGTCAGGTTCTCTT-3' | 206 | *Car* I | G yes; A No |
| *STAT3* | rs744166 | A>G | ST2f: 5'-CAGGAGTGCCAACATTGAGAG-3'  ST2r: 5'-G TAATGTCTTGAGGGA ATCGAG-3' | 106 | *Alu* I | A yes; G No |
| *HO-1* | rs2071746 | A>T | HO4f: 5'-TCAGCAGAGGATTCCAGCAGG-3'  TG-3' HO4r: 5'-AGGCAGCGCTGCTCAGAGCAC-3' | 110 | *Bfa* I | A yes; T No |

1low case letter: mismatche nucleotide.

**Table 4 Genetic association of *IL-10, IL10RA, IL10RB, STAT3,* and *HO-1* genes with pediatric inflammatory bowel disease**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP ID** | **Genotype** | **Disease (*n*)** | **Control (*n*)** | **OR** | **95%CI** | ***P* value** |
| *IL-10* | rs1800872 | CC | 89 | 78 | 0.863 | 0.564-1.313 | 0.71 |
| CA | 68 | 50 |  |  |  |
| AA | 2 | 1 |  |  |  |
| C allele | 246 | 206 |  |  |  |
| A allele | 72 | 52 |  |  |  |
| rs3024498 | CC | 86 | 77 | 0.83 | 0.552-1.244 | 0.616 |
| CT | 65 | 47 |  |  |  |
| TT | 8 | 5 |  |  |  |
| C allele | 237 | 201 |  |  |  |
| T allele | 81 | 57 |  |  |  |
| rs3024496 | AA | 57 | 27 | 1.487 | 1.055-2.099 | 0.022 |
| AG | 69 | 69 |  |  |  |
| GG | 33 | 33 |  |  |  |
| A allele | 183 | 123 |  |  |  |
| G allele | 185 | 135 |  |  |  |
| *IL10-RA* | rs3135932 | AA | 108 | 85 | 0.925 | 0.595-1.433 | 0.16 |
| AG | 39 | 40 |  |  |  |
| GG | 12 | 4 |  |  |  |
| A allele | 255 | 210 |  |  |  |
| G allele | 63 | 48 |  |  |  |
| *IL10-RB* | rs2834167 | AA | 91 | 64 | 1.318 | 0.884-1.968 | 0.203 |
| AG | 66 | 60 |  |  |  |
| GG | 2 | 5 |  |  |  |
| A allele | 248 | 188 |  |  |  |
| G allele | 70 | 70 |  |  |  |
| *STAT3* | rs744166 | GG | 64 | 49 | 0.943 | 0.662-1.340 | 0.352 |
| AG | 66 | 63 |  |  |  |
| AA | 29 | 17 |  |  |  |
| A allele | 194 | 161 |  |  |  |
| G allele | 124 | 97 |  |  |  |
| *HO-1* | rs2071746 | AA | 32 | 30 | 0.957 | 0.680-1.348 | 0.634 |
| AT | 96 | 71 |  |  |  |
| TT | 31 | 28 |  |  |  |
| A allele | 158 | 131 |  |  |  |
| T allele | 160 | 127 |  |  |  |

**Table 5 Epistatic interaction between 2 SNPs in 3 *IL-10* SNPs studied**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Epistatic model** | **rs3024496, *p* = 0.022, Bp = 0.0226** | **rs3024498, *p* = 0.616; Bp = 1** |
| rs1800872, *p* = 0.71; Bp = 1 | aa | *p* = 0.00015; Bp = 0.003 | *p* = 0.638; Bp = 1 |
| ad | *p* = 0.057; Bp = 1 | *p* = 0.605; Bp = 1 |
| da | *p* = 0.010; Bp = 0.216 | *p* = 0.977; Bp = 1 |
| dd | *p* = 0.239; bp = 1 | *p* = 0.049; Bp = 1 |
| rs3024496, *p* = 0.022, Bp = 0.0226 | aa |  | *p* = 0.371; Bp = 1 |
| ad |  | *p* = 0.222; Bp = 1 |
| da |  | *p* = 0.167; Bp = 1 |
| dd |  | *p* = 0.584; Bp = 1 |

The *p* and Bp values for each SNP are shown next to each SNP; the *p* and Bp values for each of 2-SNP interactions are shown in the 3rd and 4th column. In the 2nd column (Epistatic model), a: additive; d: dominant. For a two SNP interaction, 4 different types of interactions may occur: additive-additive (aa), additive-dominant (ad), dominant-additive (da), and dominant-dominant (dd). Bp: Bonferroni correction *p* value.

**Table 6 Gene-gene interaction between *IL-10 with IL10RA, IL10RB, STAT3*, or *HO-1* in pediatric inflammatory bowel disease**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **SNP** | **Epistatic model** | ***IL10RA* rs3135932 *p* = 0.160; Bp = 1** | ***IL10RB* rs2834167 *p* = 0.203; Bp = 1** | ***STAT3* rs744166 *p* = 0.352; Bp = 1** | ***HO-1* rs2071746 *p* = 0.634; Bp = 1** |
| *IL-10* | rs1800872 | aa | *p* = 0.046; Bp = 1 | *p* = 0.029; Bp = 1 | *p* = 0.248; Bp = 1 | *p* = 0.910; Bp = 1 |
| ad | *p* = 0.739; Bp = 1 | *p* = 0.107; Bp = 1 | *p* = 0.954; Bp = 1 | *p* = 0.617; Bp = 1 |
| da | *p* = 0.056; Bp = 1 | *p* = 0.376; Bp = 1 | *p* = 0.117; Bp = 1 | *p* = 0.569; Bp = 1 |
| dd | *p* = 0.126; Bp = 1 | *p* = 0.168; Bp = 1 | *p* = 0.036; Bp = 1 | *p* = 0.671; Bp = 1 |
| rs3024498 | aa | *p* = 0.330; Bp = 1 | *p* = 0.062; Bp = 1 | *p* = 0.143; Bp = 1 | *p* = 0.898; Bp = 1 |
| ad | *p* = 0.068; Bp = 1 | *p* = 0.629; Bp = 1 | *p* = 0.032; Bp = 1 | *p* = 0.840; Bp = 1 |
| da | *p* = 0.884; Bp = 1 | *p* = 0.307; Bp = 1 | *p* = 0.316; Bp = 1 | *p* = 0.607; Bp = 1 |
| dd | *p* = 0.265; Bp = 1 | p = 0.644; Bp = 1 | *p* = 0.029; Bp = 1 | *p* = 0.790; Bp = 1 |
| rs3024496 | aa | *p* = 0.021; Bp = 0.433 | *p* = 0.425; Bp = 1 | *p* = 0.538; Bp = 1 | *p* = 0.346; Bp = 1 |
| ad | *p* = 0.020; Bp = 0.426 | *p* = 0.495; Bp = 1 | *p* = 0.306; Bp = 1 | *p* = 0.741; Bp = 1 |
| da | *p* = 0.081; Bp = 1 | *p* = 0.189; Bp = 1 | *p* = 0.234; Bp = 1 | *p* = 0.297; Bp = 1 |
| dd | *p* = 0.967; Bp = 1 | *p* = 0.570; Bp = 1 | *p* = 0.402; Bp = 1 | *p* = 0.457; Bp = 1 |
| *IL10RB* | rs2834167 | aa | *p* = 0.403; Bp = 1 |  | *p* = 0.251; Bp = 1 | *p* = 0.128 Bp = 1 |
| ad | *p* = 0.384; Bp = 1 |  | *p* = 0.956; Bp = 1 | *p* = 0.369 Bp = 1 |
| da | *p* = 0.518; Bp = 1 |  | *p* = 0.776; Bp = 1 | *p* = 0.0018 Bp = 0.039 |
| dd | *p* = 0.176; Bp = 1 |  | *p* = 0.072; Bp = 1 | *p* = 0.289 Bp = 1 |

**Table 7 Epistatic interaction among the two *IL-10* SNPs (rs1800872 and rs3024496) and *IL10RA, IL10RB, STAT3*, or *HO-1***

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Epistatic model** | **IL10RA rs3135932 *P* = 0.16; Bp = 1** | **IL10RB rs2834167 *P* = 0.203; Bp = 1** | **STAT3 rs744166 *P* = 0.352; Bp = 1** | **HO-1 rs2071746  *P* = 0.634; Bp = 1** |
|
| Two IL10 SNPs: rs1800872 and rs3024496 aa: *P* = 0.0002; Bp = 0.003 | aaa | *P* = 0.003;  Bp = 0.099 | *P* = 0.080;  Bp = 1 | *P* = 0.175;  Bp = 1 | p = 0.216;  Bp = 1 |
| aad | *P* = 0.130;  Bp = 1 | *P* = 0.340;  Bp = 1 | *P* = 0.920;  Bp = 1 | *P* = 0.140;  Bp = 1 |

The additive-additive (aa) interaction model for the two IL-10 SNPs (rs1800872 and rs3024496) from Figure 1 was chosen for further analysis, in order to study the interaction of these two IL-10 SNPs with SNPs of 4 other genes. Two interaction models (aaa, aad) were for the two IL-10 SNPs and SNPs from each of the 4 genes. A significant *p* value (*P* = 0.003) was observed only with the IL-10 RA SNP (rs3135932). Bp: Bonferroni correction *p* value.

**Table 8 Epistatic interaction of *IL10RB* and *HO-1* with *IL-10* (3 SNPs), *IL10RA*, or *STAT3***

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Epistatic model** | **IL10 rs1800872 *P* = 0.71;**  **Bp = 1** | **IL10 rs3024498 *P* = 0.616,**  **Bp = 21** | **IL10 rs3024496 *P* = 0.022,**  **Bp = 0.0226** | **IL10RA rs3135932 *P* = 0.16; Bp = 1** | **STAT3 rs744166 *P* = 0.352; Bp = 1** |
|  |
| aa IL10RB rs2834167 & HO1 rs2071746 | aaa | *P* = 0.029;  Bp = 1 | *P* = 0.545;  Bp = 1 | *P* = 0.255;  Bp = 1 | *P* = 0.023;  Bp = 0.820 | *P* = 0.049;  Bp = 1 |
| aad | *P* = 0.127;  Bp = 1 | *P* = 0.240;  Bp = 1 | *P* = 0.928;  Bp = 1 | *P* = 0.193;  Bp = 1 | *P* = 0.554;  Bp = 1 |
| ad IL10RB rs2834167 & HO1 rs2071746 | ada | *P* = 0.394;  Bp = 1 | p = 0.824;  Bp = 1 | p = 0.242;  Bp = 1 | p = 0.444;  Bp = 1 | p = 0.436;  Bp = 1 |
| add | *P* = 0.976;  Bp = 1 | *P* = 0.406;  Bp = 1 | *P* = 0.327;  Bp = 1 | *P* = 0.644;  Bp = 1 | *P* = 0.649;  Bp = 1 |
| da IL10RB rs2834167 & HO1 rs2071746 | daa | *P* = 0.00015; BP = 0.005 | *P* = 0.489;  Bp = 1 | *P* = 0.047;  Bp = 1 | *P* = 0.008;  Bp = 0.287 | *P* = 0.014;  Bp = 0.491 |
| dad | *P* = 0.072;  Bp = 1 | *P* = 0.140;  Bp = 1 | *P* = 0.388;  Bp = 1 | *P* = 0.205;  Bp = 1 | *P* = 0.977;  Bp = 1 |
| dd IL10RB rs2834167 & HO1 rs2071746 | dda | *P* = 0.199;  Bp = 1 | *P* = 0.808;  Bp = 1 | *P* = 0.568;  Bp = 1 | *P* = 0.766;  Bp = 1 | *P* = 0.4731;  Bp = 1 |
| ddd | *P* = 0.694;  Bp = 1 | *P* = 0.958;  Bp = 1 | *P* = 0.007;  Bp = 0.242 | *P* = 0.181;  Bp = 1 | *P* = 0.057;  Bp = 1 |

Bp: Bonferroni correction *p* value. All four interaction models (aa, ad, da, and dd) of IL10RB and HO-1 were used for this analysis as well as both of the interaction models (a and d) of each gene studied were used. A total of 8 interaction models for 3 SNPs are listed. The dad model of IL10RB and HO1 with the IL-10 rs1800872 is significant (Bp = 0.005). The daa models for IL10RB and HO-1 with either IL10RA or STAT3 is weak (Bp = 0.287 and Bp = 0.491 respectively).